Skip to main content
pharmacist patient hero

AllianceRx Walgreens Pharmacy selected as exclusive distributor of Vivjoa

Vivjoa is the first FDA-approved medication to reduce the incidence of recurrent vulvovaginal candidiasis in post-menopausal women.
Levy

Walgreens specialty pharmacy patients now have exclusive access to Vivjoa, through AllianceRx Walgreens Pharmacy, a subsidiary of Walgreens.

Vivjoa (oteseconazole), manufactured by Mycovia Pharmaceuticals, is the first FDA-approved medication to reduce the incidence of recurrent vulvovaginal candidiasis in post-menopausal women or women who are not of reproductive potential, Walgreens said. 

[Read more: AllianceRx Walgreens Pharmacy launches RightGuide]

“Having Mycovia select us as the exclusive specialty pharmacy partner of Vivjoa is a testament to the thorough care and oversight of this medication provided by Walgreens specialty pharmacists,” said Tracey James, chief operating officer of Walgreens specialty enterprise. “It’s not only how we care for the patients, but winning exclusive access to a limited distribution drug is also about how we support providers by getting their patients on therapy faster.”

[Read more: AllianceRx Walgreens Pharmacy reduces annual patient prescription costs by $6M]

 

X
This ad will auto-close in 10 seconds